Home > Gastroenterology > Long-course chemoradiation versus short-course radiotherapy in rectal cancer

Long-course chemoradiation versus short-course radiotherapy in rectal cancer

Presented By
Dr Emma Holliday, MD Anderson Cancer Center, University of Texas, TX, USA
Conference
ASCO GI 2022
In a discussion of the key considerations for short-course radiotherapy (SCR) or long-course chemoradiation (LC-CRT) in the context of total neoadjuvant therapy (TNT) for patients with locally advanced rectal cancer (LARC), both options seem reasonable and evidence-based, although SCR is the preferred option in most patients [1]. “TNT is the clear standard-of-care in patients with LARC,” explained Dr Emma Holliday (MD Anderson Cancer Center, University of Texas, TX, USA). “The RAPIDO trial (NCT01558921) compared TNT with standard-of-care in patients with LARC who displayed at least one high-risk feature. TNT was favoured over the standard-of-care with regard to the primary endpoint, 3-year disease-related treatment failure (HR 0.75; P=0.019). This effect was mainly driven by distant metastases (HR 0.69; P=0.0048) [2]. In addition, the phase 3 PRODIGE 23 trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on